Keywords: Acord, Elan, Biogen Idec, Ampyra, Fampridine, FDA approval, EMEA filing, Health Canada
US FDA clears Elan/Acorda’s Ampyra to improve walking in adults with multiple sclerosis
Article | 25 January 2010
The USA’s Food and Drug Administration has approved Ampyra (dalfampridine; previously referred to as Fampridine-SR) extended release tablets to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
